Stock Movers: Oracle Dips, Amex Soars, Eli Lilly Falls on Drug Price Speculation

Oracle's AI Outlook Concerns

• 📉 Oracle (ORCL) experienced its biggest intraday drop since January, falling 7% due to concerns about its long-range financial outlook, particularly regarding AI infrastructure demand.
• 💡 Despite projecting $225 billion in annual revenue by fiscal 2030 and $144 billion from cloud infrastructure, analysts are signaling investor apprehension about the profitability of Oracle's AI investments.
• ⚠️ The company stated its AI infrastructure projects would have a 35% gross margin, but this did not alleviate market concerns, leading to an estimated $65 billion market cap reduction.

American Express Hits Record High

• 🚀 American Express (AXP) reached a record high, up 7%, driven by strong performance of its revamped Platinum credit card.
• 📈 The company raised its full-year guidance, expecting revenue growth of 9% to 10% and earnings per share between $15.20 to $15.50.
• 🌟 The CEO highlighted that demand for the refreshed Platinum card has seen the "strongest start we've ever seen," with US Platinum account acquisitions doubling post-refresh.

Eli Lilly and Novo Nordisk Affected by Drug Price Talk

• 💊 Shares of Eli Lilly (LLY) and Novo Nordisk saw declines following comments from former President Donald Trump about reducing the price of Ozempic.
• 💰 Trump suggested the cost of the diabetes drug could fall to approximately $150 a month from its current US list price of around $1,000.
• 📉 While Eli Lilly does not produce Ozempic, its stock was impacted due to its own similar weight-loss drugs, as the potential price cut could significantly affect the market expected to reach over $95 billion by 2030.